Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters.
about
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathyEzetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic functionDietary cholesterol reverses resistance to diet-induced weight gain in mice lacking Niemann-Pick C1-Like 1.Effect of ezetimibe on incretin secretion in response to the intestinal absorption of a mixed meal.The intestinal absorption of biliary and dietary cholesterol as a drug target for lowering the plasma cholesterol level.Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters.A Hamster Model of Diet-Induced Obesity for Preclinical Evaluation of Anti-Obesity, Anti-Diabetic and Lipid Modulating AgentsProtein mediators of sterol transport across intestinal brush border membrane.Physiological role of hepatic NPC1L1 in human cholesterol and lipoprotein metabolism: new perspectives and open questions.Inhibition of intestinal absorption of cholesterol by ezetimibe or bile acids by SC-435 alters lipoprotein metabolism and extends the lifespan of SR-BI/apoE double knockout mice.Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview.The role of Niemann-Pick C1 - Like 1 (NPC1L1) in intestinal sterol absorptionReduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1-/- mice.Inhibiting intestinal NPC1L1 activity prevents diet-induced increase in biliary cholesterol in Golden Syrian hamsters.Restoring Mitochondrial Function: A Small Molecule-mediated Approach to Enhance Glucose Stimulated Insulin Secretion in Cholesterol Accumulated Pancreatic beta cellsCreosote Bush (Larrea tridentata) Improves Insulin Sensitivity and Reduces Plasma and Hepatic Lipids in Hamsters Fed a High Fat and Cholesterol DietIn vivo effects of anacetrapib on preβ HDL: improvement in HDL remodeling without effects on cholesterol absorption.Comparative study of ezetimibe and atorvastatin alone and in combination on lipid profile in rats.Phytosterols protect against diet-induced hypertriglyceridemia in Syrian golden hamsters.Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol.Therapeutic effects of ezetimibe for non-alcoholic steatohepatitis in fatty liver shionogi-ob/ob mice.Endoplasmic Reticulum Lipid Flux Influences Enterocyte Nuclear Morphology and Lipid-dependent Transcriptional Responses.Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats.Ezetimibe ameliorates intestinal chylomicron overproduction and improves glucose tolerance in a diet-induced hamster model of insulin resistance.Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study.Inhibition of cholesterol absorption by SCH 58053 in the mouse is not mediated via changes in the expression of mRNA for ABCA1, ABCG5, or ABCG8 in the enterocyte.Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption.Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men.The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin.
P2860
Q28235507-4537F339-7DA5-47E9-847A-5BFF680D7B05Q28359401-F38B48EF-8300-4B4D-950E-80AA020BDB44Q34116347-991E6274-19FC-4DAF-9F27-28A445F431D9Q34357416-A1AF7375-CB26-44C3-BD1B-0F825D8B6D00Q35080633-E87F0325-E8FD-4FF1-A275-7D0CD44438D9Q35380101-74873AD6-B90F-4E69-A194-D87E6EA52B74Q35743729-84E89204-47CD-4BA0-A763-D90482BA71DAQ35838266-B0109942-B02F-4CC7-9CCB-20E785CE4A39Q36302700-7198731E-6B76-41D9-A477-867A11150DD4Q36625645-927E7CEF-31DE-4016-9E2C-8F07295D648DQ36653658-D8EDFE6A-E9B5-491C-9CA1-C58053373B4DQ36666619-0271C6B8-C21A-47E6-8420-D1B4FF6668ADQ36956106-13BB7C46-779F-4957-B7A5-2EB342737B29Q36956116-0CC79DA8-115D-4FF6-8E23-B047654A1E3BQ36990819-894E86E9-6780-4C8E-97DC-3B5E271B5053Q37045267-4E51AEFD-47C1-4537-A7AA-A6EA37C82BE0Q37163072-0C5FB4A4-E126-4ADE-A140-44E8F6012FABQ37245121-B6D8BE9E-BF39-4172-9931-09A907318CEFQ37497908-E01CDB17-2C63-4899-A644-02A8D774ED75Q37718735-9CE0C63E-244E-4FC9-8824-72F8C0537AFFQ38331528-91E777E1-DCF1-434C-8882-8AA093FB1B0AQ39364235-10FBB85E-004C-4AC3-A459-87FE33BDEAB7Q41976615-F85DEB69-EF21-4C9D-9CD3-F4F91ED7F7F8Q42662009-267C73DC-6FCC-4D91-85FB-3F76F014A89EQ43238409-F8931971-72D1-4E72-93A4-302F1B903129Q44195491-36B28359-90E9-4D83-AB7B-DFA33B10E2F2Q45226879-4F6E6AD8-8E23-470D-8AC1-96B8DDCED3D5Q46893987-6ED37AB7-4FBA-432C-97CB-48FB4769572CQ46921352-00F7225F-A14A-4A92-B83A-42F02705B76BQ54569810-723BB517-2E33-4215-B487-1271ED7733C3
P2860
Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Ezetimibe, a potent cholestero ...... ese hyperinsulinemic hamsters.
@en
Ezetimibe, a potent cholestero ...... ese hyperinsulinemic hamsters.
@nl
type
label
Ezetimibe, a potent cholestero ...... ese hyperinsulinemic hamsters.
@en
Ezetimibe, a potent cholestero ...... ese hyperinsulinemic hamsters.
@nl
prefLabel
Ezetimibe, a potent cholestero ...... ese hyperinsulinemic hamsters.
@en
Ezetimibe, a potent cholestero ...... ese hyperinsulinemic hamsters.
@nl
P2093
P1433
P1476
Ezetimibe, a potent cholestero ...... ese hyperinsulinemic hamsters.
@en
P2093
P304
P356
10.2337/DIABETES.50.6.1330
P407
P577
2001-06-01T00:00:00Z